Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

MHRA launches programme to close women’s health evidence gaps

MHRA launched a 2026-2030 programme to strengthen evidence on medicines and medical devices used by women.

Published 16 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

The UK Medicines and Healthcare products Regulatory Agency launched its Women’s Health Programme on November 16, 2026, setting out a 2026-2030 plan to improve evidence on medicines and medical devices used by women. The programme gives research teams, universities and sponsors a clearer view of the regulator’s priorities for sex-specific data, inclusive development and evidence during pregnancy and breastfeeding.

MHRA sets four priorities across the product lifecycle

The programme document organises the work around four themes: using data to improve outcomes for women; supporting innovation and product quality; improving information for pregnant and breastfeeding women; and increasing the agency’s reach and impact. Its remit extends from product development and clinical research to authorisation, monitoring and communication after products reach the market.

MHRA says the aim is to build consideration of women’s needs into evidence generation and regulatory assessment from the outset. It plans to work with patients, academics, NHS organisations, data custodians and industry. The launch announcement places the initiative within the agency’s 2030 strategy and the wider government approach to women’s health across the UK.

Sex-specific evidence and FemTech are central to the plan

Under the data theme, MHRA intends to establish a consistent process for submitting evidence disaggregated by sex throughout the product lifecycle. The programme also proposes guidance, staff training and analytical capacity to assess differences before and after authorisation. It identifies patient-reported outcomes and experiences, real-world data and advanced analysis as potential sources of evidence.

The document sets conditions around emerging methods: synthetic data and AI-supported analysis would need appropriate validation and governance, with attention to the possibility of reproducing bias. For university researchers developing such methods, the relevant opportunity is therefore tied to demonstrating their fitness for regulatory evidence generation. This connects analytical research with a specific assessment task.

A second strand focuses on technologies serving women’s health, often called FemTech. MHRA plans clearer regulatory frameworks and guidance, use cases for existing pathways, and published topics of regulatory interest to encourage earlier engagement. The programme describes these as measures to support innovation while maintaining standards for safety, quality and compliance.

Research inclusion provides the immediate context

MHRA’s launch identifies persistent gaps in research involving women, particularly during pregnancy and breastfeeding. Its programme takes a broader view of women’s health than reproductive conditions alone, encompassing conditions that affect women exclusively, disproportionately or differently. The proposed work consequently reaches across therapeutic areas and stages of life.

The Health Research Authority’s November 2 pilot findings provide a practical background to that ambition. Seven studies tested Inclusion and Diversity Plans: five from commercial sponsors and two from non-commercial sponsors. Commercial participants reported that the plans helped structure consideration of inclusion and discussions with sites. Non-commercial participants found less additional benefit because they had already addressed those questions for funding applications.

Research ethics committee feedback was mixed. Reviewers valued concise explanations of how inclusion had been considered, while long documents repeating other application material were less useful. HRA also identified access to reliable UK epidemiological data as a major challenge. These findings give university sponsors specific issues to address when preparing plans and supporting investigators.

HRA and healthcare representatives welcome the programme

In the launch announcement, Naho Yamazaki, HRA’s deputy director of policy and partnerships, welcomed the focus on evidence relevant to people who will use new treatments. She pointed to the joint HRA-MHRA Inclusion and Diversity Plan guidance as a framework for considering participants from the earliest design stages.

MHRA chief executive Lawrence Tallon said stronger evidence could improve understanding of differences in product risks and benefits and support researchers and innovators. PAGB chief executive Michelle Riddalls welcomed the connection between closing evidence gaps and responsible innovation. Independent coverage in National Health Executive and Pharmacy Business also described the launch and its research-inclusion objectives.

What researchers, universities and research offices can do

The programme makes early study design a practical starting point. Research offices supporting UK studies can use the Health Research Authority framework to help investigators explain the intended population, recruitment approach and evidence supporting inclusion decisions. The pilot findings suggest a useful emphasis on concise reasoning and suitable population data.

For university device developers and teams analysing health records, the published priorities offer a basis for discussing evidence needs with the regulator. They also make collaboration with data custodians and patients directly relevant to programme delivery. These are planning implications of MHRA’s stated objectives; each study still needs its applicable UK research approvals and the requirements relevant to its product and design.

Webinar and voluntary research phase are next

MHRA has announced an introductory webinar for December 9, from 11am to noon, covering the programme and its plans. The launch is associated with the DIA-MHRA Global Summit in London on November 16-17. These are the dated opportunities identified in the announcement for researchers and developers following the work.

Separately, HRA says it will invite more researchers and sponsors to submit voluntary Inclusion and Diversity Plans from early 2027, collecting feedback over 12 months through participating ethics committees. Research offices can prepare expressions of interest now and follow the forthcoming participation details alongside the wider UK clinical trials regulatory framework.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →